{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:19:38Z","timestamp":1795126778513,"version":"4.10.3"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate upadacitinib (UPA) effectiveness on axial and peripheral manifestations of PsA by assessing the proportion of patients achieving low disease activity (LDA) and inactive disease (ID) status for axial involvement, and MDA and DAPSA-defined remission\/LDA for peripheral domain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included PsA patients from 27 Italian rheumatology centres. Demographic, clinical and outcome data were collected at baseline, 6 and 12\u2009months. Kaplan\u2013Meier curves assessed treatment persistence. Multivariate models identified predictors of discontinuation and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 425 patients, 282 (66.4%) had peripheral PsA and 143 (33.6%) mixed (peripheral and axial) PsA. The 12-month UPA survival rate was 75.1%, higher in peripheral than mixed PsA (P\u2009=\u20090.039). Fibromyalgia was the strongest predictor of discontinuation (aHR 1.72; 95% CI: 1.08\u20132.75; P\u2009=\u20090.022). At 12\u2009months, 38.2% of patients achieved ASDAS-LDA and 20.6% reached ASDAS-ID (LUNDEX-adjusted rates were 29.4% and 15.8%, respectively). The crude 12-month MDA rate was 59.9% (47.4% after LUNDEX adjustment). Enthesitis resolved in 80.2% of patients (P\u2009&amp;lt;\u20090.001), and NSAIDs use decreased to 32.9% (P\u2009&amp;lt;\u20090.001). Overall, VAS pain decreased significantly from 71.4 to 40 (mean change \u221231.4; 95% CI: \u221242.5 to \u221233.6; P\u2009&amp;lt;\u20090.0001), with a 44% reduction, well above the minimal clinically important improvement. No major cardiovascular events were reported; most adverse events were mild, including gastrointestinal intolerance (19%), infections (9.5%) and elevated liver enzymes (14.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study confirms UPA effectiveness across PsA domains, with clinically meaningful improvements in axial involvement and pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf411","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:52:28Z","timestamp":1754049148000},"page":"6142-6150","source":"Crossref","is-referenced-by-count":4,"title":["Targeting axial and peripheral psoriatic arthritis: a retrospective observational study on the clinical relevance of upadacitinib"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-9566","authenticated-orcid":false,"given":"Giuseppe","family":"Lopalco","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Celletti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, SS. Annunziata Hospital of Chieti, \u201cG. D'Annunzio\u201d University of Chieti-Pescara , Chieti,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Morrone","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina , Messina,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Limonta","sequence":"additional","affiliation":[{"name":"Rheumatology, ASST Papa Giovanni XXIII , Bergamo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Verona , Verona,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carletto","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, University of Verona , Verona,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Public Health, University of Cagliari and Rheumatology Unit, Azienda Ospedaliero Universitaria di Cagliari , Monserrato,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Cazzato","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana , Pisa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1729","authenticated-orcid":false,"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Reumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical, Internal, Anesthesiologic and Cardiovascular, Sciences, Sapienza University of Rome , Roma,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-8423","authenticated-orcid":false,"given":"Cinzia","family":"Rotondo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia , Foggia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Leccese","sequence":"additional","affiliation":[{"name":"Department of Health Science, University of Basilicata , Potenza,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Foti","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, A.O.U. \u201cPoliclinico-San Marco\u201d , Catania,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit of Azienda Ospedaliero-Universitaria Senese, Department of Medicine, Surgery and Neurosciences, University of Siena , Siena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital , Milan,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-0376","authenticated-orcid":false,"given":"Carlo Francesco","family":"Selmi","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital , Milan,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bazzani","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2479-6958","authenticated-orcid":false,"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties, University of Palermo , Palermo,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[{"name":"Divisions of Internal Medicine and Rheumatology AOUC, Department of Experimental and Clinical Medicine, University of Florence , Firenze,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Di Penta","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, SS. Annunziata Hospital of Chieti, \u201cG. D'Annunzio\u201d University of Chieti-Pescara , Chieti,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4383-0314","authenticated-orcid":false,"given":"Alberto","family":"Lo Gullo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, ARNAS Garibaldi , Catania,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Maria","family":"Luchetti Gentiloni","sequence":"additional","affiliation":[{"name":"Clinical Medicine, Dipartimento di Scienze Cliniche e Molecolari, Universit\u00e0 Politecnica delle Marche , Ancona,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia , Pavia,","place":["Italy"]},{"name":"Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation , Pavia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine DIMED, University Hospital of Padova , Padova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-6421","authenticated-orcid":false,"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Unit\u00e0 Sanitaria Locale di Piacenza , Piacenza,","place":["Italy"]},{"name":"School of Medicine, Department of Medicine and Surgery, University of Parma , Parma,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Semeraro","sequence":"additional","affiliation":[{"name":"Rheumatology, ASL Taranto P.O. \u201cValle d\u2018Itria\u201d Martina Franca , Taranto,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Santo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, ASL BT Andria\u2014DSS4 Barletta, Barletta-Andria-Trani , Puglia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Felice","family":"Caporali","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Universit\u00e0 degli Studi di Milano , Milan,","place":["Italy"]},{"name":"Rheumatology Unit, ASST G. Pini-CTO , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2025120216035974100_keaf411-B1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11926-013-0316-4","article-title":"Psoriatic arthritis: phenotypic variance and nosology","volume":"15","author":"Eder","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2025120216035974100_keaf411-B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-021-00999-8","article-title":"Axial psoriatic arthritis","volume":"23","author":"Gladman","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2025120216035974100_keaf411-B3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B4","doi-asserted-by":"publisher","first-page":"e004080","DOI":"10.1136\/rmdopen-2024-004080","article-title":"Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort","volume":"10","author":"Koc","year":"2024","journal-title":"RMD Open"},{"key":"2025120216035974100_keaf411-B5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B6","doi-asserted-by":"publisher","first-page":"e001838","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"2025120216035974100_keaf411-B7","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.55563\/clinexprheumatol\/8l7bbk","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study","volume":"41","author":"Mease","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2025120216035974100_keaf411-B8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/art.43069","article-title":"Development of extra-musculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis","volume":"77","author":"Poddubnyy","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2025120216035974100_keaf411-B9","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology"},{"key":"2025120216035974100_keaf411-B10","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025120216035974100_keaf411-B11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of Spondylo Arthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B12","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216035974100_keaf411-B13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3899\/jrheum.201627","article-title":"Axial involvement in psoriatic arthritis: effect on peripheral arthritis and differential features with axial spondyloarthritis in South America","volume":"48","author":"Salinas","year":"2021","journal-title":"J Rheumatol"},{"key":"2025120216035974100_keaf411-B14","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"18","author":"Von Elm","year":"2007","journal-title":"Epidemiology"},{"key":"2025120216035974100_keaf411-B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216035974100_keaf411-B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/pds.3463","article-title":"Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population","volume":"23","author":"Zhou","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025120216035974100_keaf411-B17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B21","doi-asserted-by":"publisher","first-page":"e001609","DOI":"10.1136\/rmdopen-2021-001609","article-title":"Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib","volume":"7","author":"De Vlam","year":"2021","journal-title":"RMD Open"},{"key":"2025120216035974100_keaf411-B22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/art.21570","article-title":"The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden","volume":"54","author":"Kristensen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025120216035974100_keaf411-B23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.semarthrit.2021.03.007","article-title":"Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort","volume":"51","author":"Feld","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216035974100_keaf411-B24","article-title":"Characteristics of patients with psoriatic arthritis presenting with axial involvement: results of a prospective international multicenter study (AXIS) [abstract-2334]","volume":"76","author":"Torgutalp","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025120216035974100_keaf411-B25","doi-asserted-by":"publisher","first-page":"115.1","DOI":"10.1136\/annrheumdis-2018-eular.7093","article-title":"OP0129 Drug survival on anti-TNF-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors","volume":"77","author":"Lopriore","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025120216035974100_keaf411-B26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3899\/jrheum.171094","article-title":"Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"45","author":"Mease","year":"2018","journal-title":"J Rheumatol"},{"key":"2025120216035974100_keaf411-B27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-023-03182-9","article-title":"Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study","volume":"25","author":"Luchetti Gentiloni","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2025120216035974100_keaf411-B28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s40744-023-00589-3","article-title":"Treatment with upadacitinib in active psoriatic arthritis: efficacy and safety data of the first 192 patients from the UPJOINT study, a multicentre, observational study in clinical practice","volume":"10","author":"Werner","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025120216035974100_keaf411-B29","doi-asserted-by":"publisher","first-page":"1341981","DOI":"10.3389\/fimmu.2024.1341981","article-title":"Pain in axial spondyloarthritis: role of the JAK\/STAT pathway","volume":"15","author":"Selmi","year":"2024","journal-title":"Front Immunol"},{"key":"2025120216035974100_keaf411-B30","doi-asserted-by":"publisher","first-page":"152557","DOI":"10.1016\/j.semarthrit.2024.152557","article-title":"Neuropathic pain in spondyloarthritis: decoding its prevalence, risk factors, and impact on disease activity","volume":"69","author":"Lopalco","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025120216035974100_keaf411-B31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.it.2016.10.001","article-title":"Nociceptor sensory neuron\u2013immune interactions in pain and inflammation","volume":"38","author":"Pinho-Ribeiro","year":"2017","journal-title":"Trends Immunol"},{"key":"2025120216035974100_keaf411-B32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40744-024-00671-4","article-title":"Safety profile of upadacitinib up to 5 years in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis: an integrated analysis of clinical trials","volume":"11","author":"Burmester","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025120216035974100_keaf411-B33","doi-asserted-by":"publisher","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"2025120216035974100_keaf411-B34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"2025120216035974100_keaf411-B35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf411\/63940493\/keaf411.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6142\/63940493\/keaf411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/12\/6142\/63940493\/keaf411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:04:05Z","timestamp":1764709445000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/12\/6142\/8221944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,8,4]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf411","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,8,4]]}}}